2. Cell Cycle/DNA Damage Antibody-drug Conjugate/ADC Related Autophagy Anti-infection Apoptosis
  3. Topoisomerase DNA/RNA Synthesis ADC Payload Autophagy Bacterial Antibiotic Apoptosis
  4. Daunorubicin citrate

Daunorubicin citrate  (Synonyms: Daunomycincitrate; RP 13057citrate; Rubidomycincitrate)

Cat. No.: HY-108876
Handling Instructions Technical Support

Daunorubicin (Daunomycin) citrate is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin citrate inhibits DNA and RNA synthesis. Daunorubicin citrate is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin citrate is also an anthracycline antibiotic. Daunorubicin citrate can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.

For research use only. We do not sell to patients.

CAS No. : 1884557-85-0

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Daunorubicin citrate:

Other Forms of Daunorubicin citrate:

Daunorubicin citrate Related Antibodies

Top Publications Citing Use of Products

37 Publications Citing Use of MCE Daunorubicin citrate

Cell Proliferation/Viability Assay
Apoptosis Analysis
Cell Imaging/Staining

    Daunorubicin citrate purchased from MedChemExpress. Usage Cited in: Interdiscip Med. 2025 Sep 1;3(5):e70053.

    Cell viability analysis of OCI-AML2 cells expressing the indicated sgRNAs following treatment with increasing concentrations of Daunorubicin hydrochloride (3 days), assessed using the CCK-8 assay.

    Daunorubicin citrate purchased from MedChemExpress. Usage Cited in: Interdiscip Med. 2025 Sep 1;3(5):e70053.

    OCI-AML2 cells expressing indicated sgRNAs were treated with DMSO or Daunorubicin hydrochloride (10 nM), and viable cells were counted every 3–4 days.

    Daunorubicin citrate purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Jan;20(1):51-64.  [Abstract]

    Comparison of drug (Epirubicin hydrochloride, EPI; Daunorubicin hydrochloride, DNR; Vinorelbine ditartrate, VNR; Oxaliplatin, OXA; Vincristine, VCR; Artemisinin, ART; Colchicine, COL) cytotoxicity to TC1 cells at the indicated doses and time points measured with CCK-8 assays. R.U. (Relative unit) was calculated from the average O.D. values in each condition as the indicator of cell viability (n = 3).

    Daunorubicin citrate purchased from MedChemExpress. Usage Cited in: J Transl Med. 2022 Jul 6;20(1):304.  [Abstract]

    IC50 curves of Daunorubicin hydrochloride (1.25-1280 nM; 48 h) in U937 and Molm-13 cells transfected with lentivirus targeting SEMA4D or control. Transduced AML cells were treated with daunorubicin for 48 h and then measured by CCK-8 analysis.

    Daunorubicin citrate purchased from MedChemExpress. Usage Cited in: J Transl Med. 2022 Jul 6;20(1):304.  [Abstract]

    Cell apoptosis rate of U937 and Molm-13 cells transfected with lentivirus targeting SEMA4D or control after Daunorubicin hydrochloride (10-80 nM) treatment was detected by flow cytometry using Annexin V-APC /PI staining.

    Daunorubicin citrate purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2021 May 5;13(5):661.

    Primary AML cells were treated with Daunorubicin hydrochloride (DNR, 8-32 μM) and Erastin (5 μM) for 48 h, and cell viability was assessed using the CCK-8 assay.

    Daunorubicin citrate purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2021 May 5;13(5):661.

    HL-60 cells were pretreated with CCL20 for 30 min, followed by Daunorubicin hydrochloride (DNR, 1.6, 3.2 μM) treatment for 48 h, and lipid peroxidation level were measured.

    View All Topoisomerase Isoform Specific Products:

    View All Isoforms
    Topoisomerase Topo I Topo II DNA gyrase

    View All DNA/RNA Synthesis Isoform Specific Products:

    View All Isoforms
    RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

    View All ADC Payload Isoform Specific Products:

    View All Isoforms
    Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

    View All Antibiotic Isoform Specific Products:

    View All Isoforms
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Daunorubicin (Daunomycin) citrate is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin citrate inhibits DNA and RNA synthesis. Daunorubicin citrate is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin citrate is also an anthracycline antibiotic. Daunorubicin citrate can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor[1][2][4][5].

    IC50 & Target[1][2]

    Topoisomerase II

     

    Daunorubicins/Doxorubicins

     

    In Vitro

    Daunorubicin citrate (0-256 μg/mL, 30 min) inhibits DNA and RNA synthesis in sensitive and resistant Ehrlich ascites tumor cells[2].
    Daunorubicin citrate (7 nM-1.9 μM, 72 h) shows chemosensitivity in Molt-4 cells and L3.6 cells[3][4].
    Daunorubicin citrate (0.4 μM, 48 h) induces apoptotic and necrosis in L3.6 cells[4].
    Daunorubicin citrate (0.4 μM, 120 min) induces ROS generation in L3.6 cells[4].
    Daunorubicin citrate (2 μM, 24 h) induces autophagy in K562 cells (myeloid cell line)[6].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Daunorubicin citrate Related Antibodies

    Cell Viability Assay[3][4]

    Cell Line: Molt-4 cells (a human T-lymphoblastic leukemia cell line), L3.6 cells (metastatic human pancreatic cell line)
    Concentration: 7 nM-1.9 μM
    Incubation Time: 72 h
    Result: Inhibited cell viability with IC50 values of 40 nM (Molt-4) and 400 nM (L3.6).

    Apoptosis Analysis[4]

    Cell Line: L3.6 cells
    Concentration: 0.4 μM
    Incubation Time: 24 h, 48 h
    Result: Induced necrosis without apoptosis at 24 h, induced both an apoptotic and extensive necrotic response at 48 h.

    Western Blot Analysis[6]

    Cell Line: K562 cells
    Concentration: 2 μM
    Incubation Time: 24 h
    Result: Enabled the switch of LC3-I into LC3-II, accompanied with a significant increased expression level of LC3.
    In Vivo

    Daunorubicin citrate (intravenous injection, 3 mg/kg, three times at 48 h intervals) produces cardiotoxicity and nephrotoxicity in rats[5].
    Daunorubicin citrate (intraperitoneal injection, 10 mg/kg) induces sister chromatid exchanges in mice[7].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male Sprague-Dawley rats[5]
    Dosage: 3 mg/kg
    Administration: Intravenous injection, three times at 48 h intervals.
    Result: Caused a significant increase in MDA (malondialdehyde) level in renal tissue, accompanied by a significant reduction in total GPx activity.
    Increased urinary protein excretion, serum creatinine, and BUN level.
    Clinical Trial
    Molecular Weight

    719.64

    Formula

    C33H37NO17
    CAS No.
    SMILES

    OC(C(O)=O)(CC(O)=O)CC(O)=O.OC1=C2C([C@H](C[C@@](C(C)=O)(O)C2)O[C@@]3([H])C[C@@H]([C@H](O)[C@H](C)O3)N)=C(O)C4=C1C(C5=CC=CC(OC)=C5C4=O)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Purity & Documentation
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Daunorubicin citrate Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Daunorubicin1884557-85-0Daunomycincitrate RP 13057citrate RubidomycincitrateTopoisomeraseDNA/RNA SynthesisADC PayloadAutophagyBacterialAntibioticApoptosisADC CytotoxinAnti-tumorEhrlich ascites tumorpancreatic carcinoma leukemiacytotoxinMolt-4 cellL3.6 cellK562 cellschamomileInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Daunorubicin citrate
    Cat. No.:
    HY-108876
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.